ReviewClinical rheumatology2018
Two Chinese pedigrees of Blau syndrome with thirteen affected members.
Review in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Inactivation of NF-κB and MAPKs confers the potent therapeutic effect of carboxyamidotriazole on Blau syndrome.Arthritis research & therapy · 2026Article
- Clinical features, treatment strategies, and long-term outcomes of Blau syndrome: a 10-year experience from a Chinese cohort.Advances in rheumatology (London, England) · 2026Observational
- Management of Blau syndrome: review and proposal of a treatment algorithm.European journal of pediatrics · 2024Review
- Comprehensive clinical phenotype, genotype and therapy in Yao syndrome.Frontiers in immunology · 2024Article
- Blau syndrome with hypertension and hepatic granulomas: a case report and literature review.Frontiers in pediatrics · 2023Article
- Cutaneous Manifestations of Autoinflammatory Diseases.Rheumatology and immunology research · 2021Review
- Ocular manifestations in Chinese adult patients with NLRP3-associated autoinflammatory disease.Scientific reports · 2021Article
- Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome.Arthritis research & therapy · 2019Review
- Blau Syndrome Associated with Nucleotide-binding Oligomerization Domain Containing 2 Mutation in a Baby from Malaysia.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Blau syndrome (BS) is a rare autosomal dominant autoinflammatory disease characterized by the clinical triad of dermatitis, arthritis, and uveitis. It is caused by mutations in nucleotide-binding oligomerization domain-containing protein-2 (NOD2) gene. BS has been widely reported in Caucasians but cases documented in China are scarce. We reported two Chinese families with BS, which were by far the two largest pedigrees in the Chinese population. We identified two unrelated families with BS. The phenotypes and genotypes of these patients were reviewed and compared with previous cohorts. The proband of the first family was a 32-year-old Chinese Han woman, who had dermatitis, polyarthritis, and intermittent fever since the age of 6, bilateral panuveitis since 12. During her disease course, she lost her vision and developed hand flexion contractures. The proband of the second family was a 36-year-old Chinese Han woman, who had dermatitis and bilateral panuveitis since the age of 7, persistent polyarthritis since 13. Additional 7 and 4 family members were affected in the first and second families, respectively, and pedigree analysis suggested autosomal dominant inheritance. Genetic testing in both families identified the heterozygous c.1000 C > T, R334W mutation in NOD2 gene. Only one patient had recurrent fever as an expanded manifestation beyond the classical triad. BS can occur in multiple ethnic groups including the Chinese Han population. Our 11 adult patients constituted the largest adult cohort of BS ever reported in China. Lack of recognition of BS led to a significant delay in diagnosis. A considerable percentage of patients did not demonstrate the full spectrum of the classical triad, further complicating the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.